In this video from Pharmaceutical Technology, CEO Tom Sellig highlights Adare’s integrated end-to-end CDMO services, emphasizing our oral dose capabilities and small molecule expertise. He discusses recent and planned expansions, including packaging, high potency, and controlled substances offerings, along with a new nitrosamine mitigation offering.